{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28","upperLimit":"457","value":"149"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Time to progression is from the start of treatment until the first date that criteria for progressive disease (PD) are met.\n\n* 25% increase in the level of the serum monoclonal paraprotein, which must also be an absolute increase of at least 0.5 g/dL and confirmed by at lease 1 repeated investigation.\n* 25% increase in the 24 hr urinary light chain excretion, which must also be an absolute increase of at least 200 mg/ 24 hr and confirmed by at least 1 repeated investigation.\n* 35% increase in plasma cells in a bone marrow aspirate or on trephine biopsy, which must also be an absolute increase of at least 10%.\n\n  * Increase in the size of existing bone lesions or soft tissue plasmacytomas\n  * New lytic bone lesions or soft tissue plasmacytomas or definite increase in the size of residual bone lesions (development of a compression fracture does not exclude continued response and may not indicate progression).\n  * Hypercalcemia - corrected serum calcium \\> 11.5 mg/dL","dispersionType":"Full Range","groups":[{"description":"Initially patients will receive a dose of 500mg (2, 250mg tablets) in the morning and 250mg (1, 250mg tablet) in the afternoon for 2 weeks (cycle 1, days 1-14), then 500mg (2, 250mg tablets) bid for 2 weeks (cycle 1, days 15-28) and finally 750mg (3, 250mg tablets) in the morning and 500mg (2, 250mg tablets) in the afternoon for the remainder of treatment duration (cycle 2, day 1 and onwards). Each 28 days of drug administration will constitute one cycle of therapy.","id":"OG000","title":"PTK787/ZK 222584"}],"paramType":"MEDIAN","populationDescription":"Participants were evaluable for time to progression if they completed 3 cycles of treatment. 10 out of 21 participants completed 3 cycles of treatment.","reportingStatus":"POSTED","timeFrame":"Until the patient progresses or expires (up to 457 days)","title":"Time to Progression","type":"SECONDARY","unitOfMeasure":"days"}